Yellow Fever (YF) is an acute viral hemorrhagic fever disease caused by Yellow Fevervirus (YFV) and an estimated 200,000 YF infections occur annually. Approximately 50% ofinfected individuals that develop a severe case of the disease will die. The infection iscommon in Africa and South America, and travelers and residents of those areas are athigh risk of contracting the virus. A recent resurgence of YF in Africa and South Americahas exposed the YFV vaccine supply shortage that is insufficient to fight this major publichealth problem.In this project, Universal Stabilization Technologies (UST) in collaboration with University ofTexas Medical Branch (UTMB) will apply USTs novel approach for development ofthermostable, inactivated, and potent vaccine against YF starting with wild-type YFV. TheYFV will be stabilized at ambient temperatures (AT) using USTs patented Preservation byVaporization (PBV) technology and subsequently inactivated at AT using electron beam(EB) irradiation procedure to produce inactivated and potent vaccine against Yellow Fever.The EB inactivation has been found to inactivate through virus nucleic acid damage withoutaffecting virus surface structures, thus preserving integrity of epitopes, or antigenicdeterminants recognized by the immune system, while preventing virus replication.The specific aims for this project are the following: Aim 1: Produce thermostable, electron beam (EB) inactivated Yellow Fevervaccine candidate. Aim.2. Perform long-term stability testing at low, medium, and high ambienttemperatures: 4?C. 25?C. 37?C and short-term testing at 70?C. Aim 3. Evaluate protective efficacy of the YFV vaccine candidate againstviscerotropic YF in a hamster model.Our immediate goal is to prove feasibility of a safe, effective, low-cost thermostablevaccine against Yellow Fever virus. The technologies developed in this project couldeventually provide a platform technology for quick development of safe, thermostable,and effective vaccines against other emerging diseases. Public Health Relevance Statement Project NarrativeThis research first explores feasibility of producing a safe, effective, low cost thermostablevaccine against Yellow Fever virus, which could ultimately be administered to patients viarespiratory or non-needle delivery. For this project, wild-type Yellow Fever virus will bethermostabilized by Universal Stabilization Technologies innovative Preservation byVaporization process, followed by electron beam inactivation to create a potent vaccine.The technologies developed in this project could eventually become a platform technologyfor quick development of safe, effective, and thermostable vaccines against otherinfectious diseases.
Project Terms: Affect ; Africa ; Elderly ; advanced age ; elders ; geriatric ; late life ; later life ; older adult ; older person ; senior citizen ; Epitopes ; Antigenic Determinants ; Binding Determinants ; Blood Chemical Analysis ; Blood Chemical Analyses ; blood chemistry ; Body Weight ; Carbohydrates ; Clinical Chemistry ; Communicable Diseases ; Infectious Disease Pathway ; Infectious Diseases ; Infectious Disorder ; Disease ; Disorder ; Electron Beam ; Epidemic ; Freeze Drying ; Freeze Dryings ; Lyophilization ; Glass ; Goals ; Hamsters ; Cricetinae ; Hamsters Mammals ; Viral Hemorrhagic Fevers ; hemorrhagic fever ; Immobilization ; orthopedic freezing ; Immune system ; allergic/immunologic body system ; allergic/immunologic organ system ; Infection ; Laboratories ; mortality ; Nucleic Acids ; Legal patent ; Patents ; Patients ; Pregnant Women ; expectant mother ; expecting mother ; pregnant mothers ; Production ; Public Health ; Research ; Rubber ; Latex Rubber ; natural Rubber ; seal ; South America ; Technology ; Temperature ; Testing ; Texas ; Tissues ; Body Tissues ; Travel ; Universities ; Vaccination ; Vaccines ; Vacuum ; Viral Proteins ; Viral Gene Products ; Viral Gene Proteins ; virus protein ; Virus Replication ; viral multiplication ; viral replication ; virus multiplication ; Virus ; Yellow Fever ; Yellow fever virus ; Measures ; Immunocompromised Host ; Immunocompromised ; Immunocompromised Patient ; Immunosuppressed Host ; immunosuppressed patient ; Organ ; Vial device ; Vial ; Procedures ; Area ; Surface ; Acute ; Phase ; Medical ; Serum ; Blood Serum ; Individual ; Functional disorder ; Dysfunction ; Physiopathology ; pathophysiology ; Collaborations ; Cold Chains ; vaccine against yellow fever ; yellow fever virus vaccine ; Yellow Fever Vaccine ; Attenuated ; Contracting Opportunities ; Contracts ; Viral Burden ; Viral Load ; Viral Load result ; fighting ; Investigation ; Hour ; Clinic ; neutralizing antibody ; respiratory ; Adverse reactions ; vaporization ; innovative technologies ; success ; thermolability ; thermostability ; Structure ; novel technologies ; new technology ; Modeling ; evaluate vaccines ; vaccine screening ; vaccine testing ; vaccine evaluation ; irradiation ; preventing ; prevent ; Age-Years ; Small Business Technology Transfer Research ; STTR ; Vaccinated ; Process ; Development ; developmental ; cost ; novel strategies ; new approaches ; novel approaches ; novel strategy ; pathogen ; aged ; protective effect ; high risk ; pregnant ; vaccine candidate ; protective efficacy ; process optimization ; stability testing ; Formulation ; preservation ;
